Starton Therapeutics Completes One Third of STAR-LLD Study Enrollment Two patients have been dosed and a third is in screeningThe first patient has completed cycle 1 successfully where he obtained a measurable response with a decrease in M-protein from 1.7 to 0.9 gm/dL...